ATE445603T1 - Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung - Google Patents

Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung

Info

Publication number
ATE445603T1
ATE445603T1 AT02005248T AT02005248T ATE445603T1 AT E445603 T1 ATE445603 T1 AT E445603T1 AT 02005248 T AT02005248 T AT 02005248T AT 02005248 T AT02005248 T AT 02005248T AT E445603 T1 ATE445603 T1 AT E445603T1
Authority
AT
Austria
Prior art keywords
polymorphs
donepezil hydrochloride
production
peaks
hydrochloride
Prior art date
Application number
AT02005248T
Other languages
German (de)
English (en)
Inventor
Hideaki Watanabe
Akio Imai
Takashi Kajima
Yasushi Ishihama
Akiyo Ohtsuka
Tomohide Tanaka
Yukio Nabaru
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15404413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445603(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE445603T1 publication Critical patent/ATE445603T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AT02005248T 1996-06-07 1997-06-06 Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung ATE445603T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP14629396 1996-06-07
PCT/JP1996/003881 WO1997046526A1 (en) 1996-06-07 1996-12-27 Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US08/774,802 US6140321A (en) 1996-06-07 1996-12-30 Polymorphs of donepezil hydrochloride and process for production

Publications (1)

Publication Number Publication Date
ATE445603T1 true ATE445603T1 (de) 2009-10-15

Family

ID=15404413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02005248T ATE445603T1 (de) 1996-06-07 1997-06-06 Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung

Country Status (16)

Country Link
US (1) US6140321A (https=)
JP (2) JP2005015486A (https=)
KR (1) KR100545851B1 (https=)
CN (1) CN1312129C (https=)
AT (1) ATE445603T1 (https=)
AU (1) AU1153097A (https=)
CA (1) CA2516108C (https=)
DE (1) DE69739622D1 (https=)
DK (1) DK1211243T3 (https=)
ES (1) ES2330997T3 (https=)
HU (1) HUP0900417A3 (https=)
PT (1) PT1211243E (https=)
SI (1) SI22888B (https=)
UA (1) UA60307C2 (https=)
WO (1) WO1997046526A1 (https=)
ZA (1) ZA975064B (https=)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009981A1 (en) * 1997-08-21 1999-03-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
US6274603B1 (en) 1997-09-24 2001-08-14 Mcgill University Methods for increasing ApoE levels for the treatment of neurodegenerative disease
DK1140090T3 (da) 1999-01-07 2005-04-18 Gerolymatos P N Sa Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt
US6677330B1 (en) 1999-03-03 2004-01-13 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
EP2133078A1 (en) 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
WO2002026709A1 (en) * 2000-09-25 2002-04-04 Eisai Co., Ltd. Process for producing multiform crystal of donepezil hydrochloride
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
KR20040075371A (ko) * 2002-02-07 2004-08-27 에-자이가부시기가이샤 발모 촉진제, 경피 적용 제제 및 발모 촉진 방법
DE60232103D1 (de) * 2002-05-01 2009-06-04 San Ei Gen Ffi Inc Verfahren zur modifizierung von gummi arabicum
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US20050288330A1 (en) * 2004-06-29 2005-12-29 Avinash Naidu Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
WO2004099142A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
EP1773339A4 (en) * 2004-07-30 2009-07-29 Reddys Lab Ltd Dr CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
DK1797038T3 (da) * 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
WO2006035433A2 (en) * 2004-09-29 2006-04-06 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
ES2317313T3 (es) * 2004-10-19 2009-04-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Composicion farmaceutica solida que comprende clorhidrato de donepezilo.
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
US20060122226A1 (en) * 2004-12-08 2006-06-08 Itai Adin Crystalline forms of Donepezil base
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
WO2007018801A1 (en) * 2005-07-28 2007-02-15 Teikoku Pharma Usa, Inc. Gelled donepezil compositions and methods for making and using the same
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7274339B2 (en) * 2005-09-16 2007-09-25 Smartant Telecom Co., Ltd. Dual-band multi-mode array antenna
DE102005060377A1 (de) 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008117123A2 (en) * 2006-10-16 2008-10-02 Medichem, S.A. Process for preparing donepezil hydrochloride polymorphic form i
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
US20100063112A1 (en) * 2006-11-09 2010-03-11 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
EP2089363A1 (en) * 2006-11-14 2009-08-19 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide
WO2008111590A2 (en) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
WO2008139984A1 (en) * 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Cinnamide compounds for dementia
WO2009084030A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd. Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5488956B2 (ja) * 2008-11-25 2014-05-14 株式会社Ｄｎｐファインケミカル宇都宮 （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩のＩ形結晶とＩＩ形結晶の混晶の製造法
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2011061591A1 (en) 2009-11-18 2011-05-26 Jubilant Life Sciences Limited Improved process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanone)-2-yl)methyl piperidine hydrochloride form-iii
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
NZ602872A (en) * 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
US20130267560A1 (en) 2010-10-22 2013-10-10 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103012247B (zh) * 2013-01-18 2014-12-10 浙江东亚药业有限公司 一种盐酸多奈哌齐无水i晶型的制备方法
CN103965188A (zh) * 2013-01-29 2014-08-06 中山大学 含硒多奈哌齐类似物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN106397306B (zh) * 2016-10-20 2019-03-08 山东罗欣药业集团股份有限公司 一种盐酸多奈哌齐晶型化合物及其制备方法
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
BR112021024054A2 (pt) 2019-05-31 2022-01-11 Tecnimede Sociedade Tecnico Medicinal Sa Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos.
IL321722A (en) 2022-12-28 2025-08-01 Corium Llc Premixing method for preparing a transdermal delivery system
EP4642433A1 (en) 2022-12-28 2025-11-05 Corium, LLC Method of preparing transdermal delivery system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi

Also Published As

Publication number Publication date
JP2009040783A (ja) 2009-02-26
DK1211243T3 (da) 2010-02-08
UA60307C2 (uk) 2003-10-15
HUP0900417A3 (en) 2012-12-28
DE69739622D1 (de) 2009-11-26
CA2516108C (en) 2008-12-02
HU0900417D0 (en) 2009-08-28
KR100545851B1 (ko) 2006-01-24
KR20040104707A (ko) 2004-12-10
CN1699343A (zh) 2005-11-23
WO1997046526A1 (en) 1997-12-11
JP2005015486A (ja) 2005-01-20
SI22888A (sl) 2010-04-30
US6140321A (en) 2000-10-31
CA2516108A1 (en) 1997-12-11
SI22888B (sl) 2010-06-30
CN1312129C (zh) 2007-04-25
ZA975064B (en) 1998-04-01
ES2330997T3 (es) 2009-12-18
HK1080078A1 (en) 2006-04-21
AU1153097A (en) 1998-01-05
PT1211243E (pt) 2009-11-06

Similar Documents

Publication Publication Date Title
ATE445603T1 (de) Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung
CA2252806A1 (en) Polymorphs of donepezil hydrochloride and process for production
HUP0000610A3 (en) Piperidine derivatives, with analgesic effect, process for producing them and pharmaceutical compositions containing them
DE69618515D1 (de) Geriffelter teig und verfahren zur herstellung des geriffelten teigs
DE69739561D1 (de) Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
NO982712D0 (no) FremgangsmÕter og mellomprodukter for fremstilling av 1-benzyl-4-((5,6-dimetoksy-1-indanon)-2-yl)metylpiperidin
DE69506431D1 (de) Stärkeprodukte als tablettierhilfstoff, verfahren zu deren herstellung und verfahren zur herstellung von tabletten
DE602004024129D1 (de) 1-benzyl-4-ä(5,6-dimethoxy-1-indanon)-2-ylümethylpiperidinoxalat und dessen polymorphen
ATE230396T1 (de) Polymorphe von donepezyl-hydrochlorid und verfahren zur herstellung
NO970023D0 (no) Fremgangsmåte for fremstilling av en anatase-titandioksyd, og anatase-titandioksyd oppnådd derved
DE69300062D1 (de) Verfahren zur Herstellung von N-Methoxyderivate von 4-Hydroxy-2,2,6,6-Tetramethylpiperidin und 2,2,6,6-Tetramethyl-4-Piperidon.
DE69628540D1 (de) Racemisierungsverfahren zur herstellung von levobupivacain und verwandte piperidin carboxanilide mit anästhetischer wirkung
DE69711634D1 (de) Verfahren zur herstellung von platinum oder palladium benzoporphyrinen und cyclohexenoporphyrinen, zwischenprodukte und sauerstoffsensor
DE69703554D1 (de) VERFAHREN ZUR HERSTELLUNG VON N- (1-n-BUTYL-4-PIPERIDINYL)METHYL] -3,4-DIHYDRO -2H-[1,3]OXAZINO[3,2-a]INDOL-10-CARBOXAMID UND SALZE SOWIE ZWISCHENPRODUKTE IN DEM VERFAHREN
FI901874A0 (fi) Menetelmä titaanidioksidin valmistamiseksi
NO20002450L (no) Sammenstilling av aktive bestanddeler, særlig tetrahydropyridiner og acetylcholinesterase-inhiberende midler, for behandling av senil demens av Alzheimer-type
ATE260983T1 (de) Verfahren zur herstellung von 4-(4-(4- (hydroxydiphenyl)-1-piperidinyl)-1-hydroxybutyl - alpha,alpha-dimenthylphenylessigsäure und phosphorylierter derivate
HUP0002270A2 (hu) Donepezil-hidroklorid polimorf módosulatai, eljárás ezek előállítására, valamint e módosulatokat tartalmazó gyógyászati készítmények
FI885254A7 (fi) Menetelmä titaanidioksidin valmistamiseksi hajottamalla titaanikuonapitoista lähtöainetta ja ilmeniittiä
PT86211A (de) Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
PL303978A1 (en) Novel derivatives of piperidine and piperazine, method of obtaining them as well as pharmaceutical preparation and method of obtaining same
DE69618486D1 (de) Verfahren zum herstellen von riechstoffkompositionen und riechstoffprodukten und so erhaltene produkte
FI941480L (fi) 1,2,5,6-tetrahydropyridiinijohdannainen, menetelmä sen valmistamiseksi ja sen käyttö terapiassa
FI92578C (fi) Menetelmä titaanidioksidin valmistamiseksi
FI946041L (fi) Menetelmä titaanidioksidin valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1211243

Country of ref document: EP